The standard treatment of acute lymphoblastic leukemia

doi:10.3969/j.issn.1004-583X.2021.10.002

Abstract

Abstract:

Acute lymphoblastic leukemia(ALL) is a highly heterogeneous hematological malignancy resulting from clonal proliferation of lymphoid precursor cells. In recent years, with the optimization of risk stratification model and the emergence of new drugs, such as tyrosine kinase inhibitors, monoclonal antibodies, chimeric antigen receptor T cells and other targeted drugs, the outcomes of ALL patients have been greatly improved. This article briefly described the current standards for treatment of ALL. Also, the latest progress in the therapy of ALL were discussed.

Key words: leukemia, lymphoid tissue, molecular targeted therapy, antibodies,monoclonal

CLC Number:

R733.7

Lu Wenyi, Zhao Mingfeng. The standard treatment of acute lymphoblastic leukemia[J]. Clinical Focus, 2021, 36(10): 874-879.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.10.002

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I10/874

Figures/Tables 1

References 39

[1]	NCCN clinical practice guidelines in oncology acute lymphoblastic leukemia. Version 1.2020[R/OL]. [2020-01-15].
[2]	Kruse A, Abdel-Azim N, Kim HN, et al. Minimal residual disease detection in acute lymphoblastic leukemia[J]. Int J Mol Sci, 2020,21(3):1054. doi: 10.3390/ijms21031054 URL
[3]	Short NJ, Jabbour E. Minimal residual disease in acute lymphoblastic leukemia: How to recognize and treat it[J]. Curr Oncol Rep, 2017,19(1):6. doi: 10.1007/s11912-017-0565-x URL
[4]	Bassan R, Intermesoli T, Scattolin A, et al. Minimal residual disease assessment and risk-based therapy in acute lymphoblastic leukemia[J]. Clin Lymphoma Myeloma Leuk, 2017,17S:S2-S9.
[5]	Zhao XS, Liu YR, Xu LP, et al. Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts[J]. Am J Hematol, 2019,94(5):512-521. doi: 10.1002/ajh.v94.5 URL
[6]	Raff T, Gokbuget N, Luschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: Data from the GMALL 06/99 and 07/03 trials[J]. Blood, 2007,109(3):910-915. doi: 10.1182/blood-2006-07-037093 URL
[7]	秘营昌. 成人急性淋巴细胞白血病的规范化诊断及治疗[J]. 临床血液学杂志, 2012,25(3):1004-2806.
[8]	中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组. 中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J]. 中华血液学杂志, 2016,37(10):837-845.
[9]	Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias[J]. N Engl J Med, 2013,369(19):1783-1796. doi: 10.1056/NEJMoa1306494 URL
[10]	Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: Long-term follow-up of a single-centre, phase 2 study[J]. Lancet Haematol, 2018,5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5 URL
[11]	Richards S, Pui CH, Gayon P, et al. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2013,60(2):185-195. doi: 10.1002/pbc.24228 pmid: 22693038
[12]	Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl J Med, 2018,378(5):439-448. doi: 10.1056/NEJMoa1709866 URL
[13]	Pasquini M, Hu Z, Zhang Y, et al. Real world experience of tisagenlecleucel chimeric antigen receptor (CAR) T-Cells targeting CD19 in patients with acute lymphoblastic leukemia (ALL) and diffuse large B-Cell lymphoma (DLBCL) using the Center for International Blood and Marrow Transplant Research (CIBMTR) cellular therapy (CT) Registry[J]. Clin Lymphoma Myeloma Leuk, 2019,19(Suppl 1):S267.
[14]	He X, Xiao X, Li Q, et al. Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL[J]. Leukemia, 2019,33(8):2102-2104. doi: 10.1038/s41375-019-0437-5 URL
[15]	Lu W, Wei Y, Cao Y, et al. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease[J]. Cancer Immunol Immunother, 2021,70(12):3501-3511. doi: 10.1007/s00262-021-02941-4 URL
[16]	Xiao X, He X, Li Q, et al. Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-T cell infusion: A case report[J]. Clin Cancer Res, 2019,25(1):29-34. doi: 10.1158/1078-0432.CCR-18-1379 pmid: 30322878
[17]	Wan X, Chen YH, Zhang Y. Hemofiltration successfully eliminates severe cytokine release syndrome following CD19 CAR-T-cell therapy[J]. J Immunother, 2018,41(9):406-410. doi: 10.1097/CJI.0000000000000243 URL
[18]	Chevallier P, Pigneux A, Robillard N, et al. Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: A pilot series[J]. Leuk Res, 2012,36(3):311-315. doi: 10.1016/j.leukres.2011.11.010 URL
[19]	Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia[J]. J Clin Oncol, 2010,28(24):3880-3889. doi: 10.1200/JCO.2009.26.9456 URL
[20]	Jabbour E, Richard-Carpentier G, Sasaki Y, et al. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: A single-arm, phase 2 trial[J]. Lancet Haematol, 2020,7(7):e523-e533. doi: 10.1016/S2352-3026(20)30144-7 pmid: 32589978
[21]	Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia[J]. N Engl J Med, 2017,376(9):836-847. doi: 10.1056/NEJMoa1609783 URL
[22]	Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: Results from a phase Ⅱ, single-arm, multicenter study[J]. J Clin Oncol, 2017,35(16):1795-1802. doi: 10.1200/JCO.2016.69.3531 pmid: 28355115
[23]	Topp MS, Gokbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia[J]. J Clin Oncol, 2014,32(36):4134-4140. doi: 10.1200/JCO.2014.56.3247 pmid: 25385737
[24]	Zugmaier G, Gokbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment[J]. Blood, 2015,126(24):2578-2584. doi: 10.1182/blood-2015-06-649111 pmid: 26480933
[25]	Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia[J]. Blood, 2018,131(14):1522-1531. doi: 10.1182/blood-2017-08-798322 URL
[26]	Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia[J]. N Engl J Med, 2016,375(8):740-753. doi: 10.1056/NEJMoa1509277 URL
[27]	Naik J, Themeli M, de Jong-Korlaar R, et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia[J]. Haematologica, 2019,104(3):e100-e103. doi: 10.3324/haematol.2018.192757 URL
[28]	Ofran Y, Ringelstein-Harlev S, Slouzkey I, et al. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia[J]. Leukemia, 2020,34(1):293-295. doi: 10.1038/s41375-019-0548-z URL
[29]	Zhang Y, Xue S, Liu F, et al. Daratumumab for quick and sustained remission in post-transplant relapsed/refractory acute lymphoblastic leukemia[J]. Leuk Res, 2020; 91:106332. doi: 10.1016/j.leukres.2020.106332 URL
[30]	Ganzel C, Kharit M, Duksin C, et al. Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia[J]. Haematologica, 2018,103(10):e489-e490. doi: 10.3324/haematol.2018.197640 URL
[31]	Chonghaile TN, Roderick JE, Glenfield C, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199[J]. Cancer Discov, 2014,4(9):1074-1087. doi: 10.1158/2159-8290.CD-14-0353 pmid: 24994123
[32]	Leonard JT, Rowley JS, Eide CA, et al. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Sci Transl Med, 2016, 8(354):354ra114.
[33]	Pullarkat VA, Lacayo NJ, Jabbour E, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma[J]. Cancer Discov, 2021,11(6):1440-1453. doi: 10.1158/2159-8290.CD-20-1465 URL
[34]	Jain N, Stevenson KE, Winer ES, et al. A multicenter phase Ⅰ study combining venetoclax with mini-hyper-CVD in older adults with untreated and relapsed/refractory acute lymphoblastic leukemia[J]. Blood, 2019,134(Suppl 1):3867. doi: 10.1182/blood-2019-129988 URL
[35]	Horton TM, Whitlock JA, Lu X, et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: A report from the Children's Oncology Group[J]. Br J Haematol, 2019,186(2):274-285.
[36]	Bertaina A, Vinti L, Strocchio L, et al. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood[J]. Br J Haematol, 2017,176(4):629-636. doi: 10.1111/bjh.2017.176.issue-4 URL
[37]	Hasegawa D, Yoshimoto Y, Kimura S, et al. Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia[J]. Int J Hematol, 2019,110(5):627-634. doi: 10.1007/s12185-019-02714-x pmid: 31401767
[38]	Burke MJ, Ziegler DS, Sirvent F, et al. Phase 1b study of carfilzomib in combination with induction chemotherapy in children with relapsed or refractory acute lymphoblastic leukemia (ALL)[J]. Blood, 2019,134(Suppl 1):3873. doi: 10.1182/blood-2019-127350 URL
[39]	Fisch SC, Jonas BA, Tuscano J, et al. Phase I study of escalating doses of carfilzomib with Hyper-CVAD in patients with newly diagnosed acute lymphoblastic leukemia[J]. Am J Hematol, 2019,134(Suppl 1):3884.